Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.45 EUR
Change Today -0.12 / -0.95%
Volume 39.1K
BCART On Other Exchanges
EN Brussels
As of 11:35 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

biocartis nv (BCART) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/25/15 - €14.95
52 Week Low
04/24/15 - €11.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOCARTIS NV (BCART)

Related News

No related news articles were found.

biocartis nv (BCART) Related Businessweek News

No Related Businessweek News Found

biocartis nv (BCART) Details

Biocartis Group NV engages in the development and marketing of assays in oncology and infectious diseases segments through its molecular diagnostics platform. It is developing assays for oncology, including Idylla BRAF Mutation Test, an In vitro diagnosis assay for the automated detection of B-raf V600 mutations (E/E2/D/K/R/M) in formalin fixed, paraffin embedded samples; KRAS assay, a sample-to-result test that detects 21 mutations in all clinically relevant KRAS codons in colorectal cancers in one cartridge The company’s assays for oncology also comprises Neuroblastoma RAS viral (v-ras) oncogene (NRAS), NRAS/BRAF, and NRAS/BRAF/EGFR492 assays are three sample-to-result tests for the detection of mutations in the extended series of 19 NRAS mutations and Serine/threonine-protein kinase B-raf (BRAF) codon 600 for the NRAS/BRAF assay, as well as the epidermal growth factor receptor S492R mutation for the NRAS/ BRAF/EGFR492 assays, as well as MSI assay for colorectal cancers and liquid biopsy testing assays. In addition, it developing Idylla-Enrich, a pre-enrichment platform for bloodstream infections, intended to be used in conjunction with the sepsis assay; Influenza Virus—Respiratory Syncytial Virus, a respiratory tract panel assay; and a respiratory MP (mixed panel) assay; human immunodeficiency, and hepatitis C virus viral load assays; and an Ebola assay. The company has a license and development agreement with Janssen Pharmaceutica NV and bioMérieux SA; and a framework collaboration agreement with Abbott Molecular. Biocartis Group NV was founded in 2007 and is based in Mechelen, Belgium.

204 Employees
Last Reported Date: 09/16/15
Founded in 2007

biocartis nv (BCART) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biocartis nv (BCART) Key Developments

Biocartis Announces Consolidated Earnings Results for the First Half Year Ended June 30, 2015

Biocartis announced consolidated earnings results for the first half year ended June 30, 2015. For the period, the company reported revenue of EUR 6.578 million against EUR 1.124 a year ago. Operational loss was EUR 16.823 million against EUR 15.563 a year ago. Net loss was EUR 16.915 million against EUR 19.746 a year ago. Cash flow from operating activities was EUR 8.719 million against EUR 16.808 a year ago. The increase in revenue is driven by increased collaboration revenues received under the license and development agreements with Janssen Pharmaceutica for an amount of EUR 4.6 million and by an increase in product sales of EUR 0.9 million.

Biocartis Group NV, H1 2015 Earnings Call, Sep 11, 2015

Biocartis Group NV, H1 2015 Earnings Call, Sep 11, 2015

Biocartis Group NV Auditor Raises 'Going Concern' Doubt

Biocartis Group NV filed its Annual on Apr 14, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCART:BB €12.45 EUR -0.12

BCART Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCART.
View Industry Companies

Industry Analysis


Industry Average

Valuation BCART Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.3x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCARTIS NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at